His primary areas of study are Biochemistry, Receptor, Protein structure, Peptide sequence and Signal transduction. His Receptor study combines topics from a wide range of disciplines, such as Tumor necrosis factor alpha, Peptidomimetic and Antibody. His research investigates the connection with Antibody and areas like Cancer which intersect with concerns in Cancer research.
His studies in Protein structure integrate themes in fields like Leucine, Biophysics, Alanine and Folding. His Signal transduction research includes elements of Osteoprotegerin, Endocrinology, Osteoclast, Internal medicine and HER2/neu. His ERBB Family study integrates concerns from other disciplines, such as Molecular biology and Monoclonal antibody.
Ramachandran Murali focuses on Cancer research, Biochemistry, Receptor, Molecular biology and Peptide. His Cancer research research is multidisciplinary, relying on both Cancer, Breast cancer, Metastasis, Protein kinase B and PI3K/AKT/mTOR pathway. Ramachandran Murali frequently studies issues relating to Biophysics and Biochemistry.
The concepts of his Receptor study are interwoven with issues in Tumor necrosis factor alpha, Endocrinology and Cell biology. Ramachandran Murali combines subjects such as Recombinant DNA, Fusion protein and Epitope, Antibody, Monoclonal antibody with his study of Molecular biology. His biological study deals with issues like Peptide sequence, which deal with fields such as Amino acid.
Ramachandran Murali mostly deals with Cancer research, Cancer, Internal medicine, Metastasis and Protein kinase B. His studies deal with areas such as Leukemia inhibitory factor receptor, Carcinogenesis, LRP5, Breast cancer and PI3K/AKT/mTOR pathway as well as Cancer research. Ramachandran Murali has researched Internal medicine in several fields, including Endocrinology and Oncology.
His Endocrinology study incorporates themes from Receptor, Arthritis, Cartilage and RANKL. The study incorporates disciplines such as Mesenchymal cell proliferation, Mesenchymal stem cell, Cell biology and Immunology in addition to Receptor. His LRP6 research is multidisciplinary, incorporating perspectives in Molecular biology and Hepatic stellate cell.
Ramachandran Murali mostly deals with Cancer research, Protein kinase B, Immune system, PI3K/AKT/mTOR pathway and Bioinformatics. His Cancer research research is multidisciplinary, incorporating elements of Breast cancer, Trastuzumab, Molecular biology, Metastasis and LRP6. The Immune system study combines topics in areas such as Peptide sequence, Computational biology and Complementarity.
His research integrates issues of Mimotope and Molecular mimicry, Antigen in his study of Bioinformatics. His Peptide study necessitates a more in-depth grasp of Biochemistry. His Biochemistry research incorporates themes from Bone regeneration and Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang;Alan Berezov;Qiang Wang;Geng Zhang.
Journal of Clinical Investigation (2007)
HER2/Neu: mechanisms of dimerization/oligomerization
Patrick J Brennan;Toru Kumagai;Alan Berezov;Ramachandran Murali.
Oncogene (2000)
Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.
Byeong Woo Park;Hong Tao Zhang;Chuanjin Wu;Alan Berezov.
Nature Biotechnology (2000)
Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis.
Jing Xue;Vishal Sharma;Michael H. Hsieh;Ajay Chawla.
Nature Communications (2015)
Polymersomes: A new multi-functional tool for cancer diagnosis and therapy
Dalia Hope Levine;P. Peter Ghoroghchian;Jaclyn Freudenberg;Geng Zhang.
Methods (2008)
The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution.
F. K. Athappilly;R. Murali;J. J. Rux;Zhaoping Cai.
Journal of Molecular Biology (1994)
Role of tryptophan repeats and flanking amino acids in Myb-DNA interactions.
Pothana Saikumar;Ramachandran Murali;E. Premkumar Reddy.
Proceedings of the National Academy of Sciences of the United States of America (1990)
Structure–based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor
Wataru Takasaki;Yuri Kajino;Kiichi Kajino;Ramachandran Murali.
Nature Biotechnology (1997)
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss
Kazuhiro Aoki;Hiroaki Saito;Cecile Itzstein;Masaji Ishiguro.
Journal of Clinical Investigation (2006)
Therapeutic peptides and peptidomimetics.
Thomas Kieber-Emmons;Ramachandran Murali;Mark I Greene.
Current Opinion in Biotechnology (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Pennsylvania
University of Pennsylvania
University of Arkansas for Medical Sciences
Cedars-Sinai Medical Center
National Institutes of Natural Sciences
Shanghai Jiao Tong University
Cedars-Sinai Medical Center
University of Southern California
University of Utah
North Shore University Hospital
Queen Mary University of London
Hong Kong Polytechnic University
Texas A&M University
National Taiwan University of Science and Technology
Semnan University
Universitat Politècnica de Catalunya
Indian Institute of Science
North Carolina State University
University of Leeds
Osaka University
University of Minnesota
Pennsylvania State University
University of Ioannina
The University of Texas MD Anderson Cancer Center
Lancaster University
London School of Economics and Political Science